The GD treatment literature has methodological limitations including inconsistent diagnostic approaches, relatively short follow-ups, and high between-studies heterogeneity. Current evidence suggests treatment can effectively reduce symptoms and gaming time, with sustained benefits at follow-up, regardless of comorbidity. High heterogeneity suggests larger, longer-term trials are needed. Pharmacological interventions require further study, alone or combined with psychological therapies.